PURPOSE: Vitamin D is a relatively inexpensive drug yet an important hormone in terms of calcium and bone homeostasis. Treatment with vitamin D is associated with reduced fracture risk particularly in an elderly population. Therefore, we assessed the budgetary impact of routine prescription of 800 IU daily colecalciferol on hip fracture among older adults in the United Kingdom. METHODS: Using meta-analysis findings for treatment effect and UK-estimates of incidence, we performed a health economic evaluation of treating the UK population aged 65 and over with 800 IU of vitamin D daily, assessing the impact upon hip fracture costs using incremental attributable costs and excess mortality for a range of age- gender-based treatment strategies. RESULTS: Using only a 1-year horizon, considering only reduction in hip fracture, prescribing colecalciferol 800 IU daily to all adults aged 65 and over, could reduce the number of incident hip fractures from 65,400 to 45,700, saving almost 1,700 associated deaths, whilst saving the UK taxpayer £22 million. CONCLUSIONS: As the UK government seeks to reduce public expenditure in all sectors, investment in prescribed prophylactic colecalciferol 800 IU therapy for adults aged 65 and over is likely to yield cost savings through reduction hip fracture alone in the first year.
PURPOSE:Vitamin D is a relatively inexpensive drug yet an important hormone in terms of calcium and bone homeostasis. Treatment with vitamin D is associated with reduced fracture risk particularly in an elderly population. Therefore, we assessed the budgetary impact of routine prescription of 800 IU daily colecalciferol on hip fracture among older adults in the United Kingdom. METHODS: Using meta-analysis findings for treatment effect and UK-estimates of incidence, we performed a health economic evaluation of treating the UK population aged 65 and over with 800 IU of vitamin D daily, assessing the impact upon hip fracture costs using incremental attributable costs and excess mortality for a range of age- gender-based treatment strategies. RESULTS: Using only a 1-year horizon, considering only reduction in hip fracture, prescribing colecalciferol 800 IU daily to all adults aged 65 and over, could reduce the number of incident hip fractures from 65,400 to 45,700, saving almost 1,700 associated deaths, whilst saving the UK taxpayer £22 million. CONCLUSIONS: As the UK government seeks to reduce public expenditure in all sectors, investment in prescribed prophylactic colecalciferol 800 IU therapy for adults aged 65 and over is likely to yield cost savings through reduction hip fracture alone in the first year.
Authors: Goran Bjelakovic; Lise Lotte Gluud; Dimitrinka Nikolova; Kate Whitfield; Jørn Wetterslev; Rosa G Simonetti; Marija Bjelakovic; Christian Gluud Journal: Cochrane Database Syst Rev Date: 2011-07-06
Authors: Lia Gutiérrez; Neil Roskell; Jordi Castellsague; Steve Beard; Catherine Rycroft; Shaun Abeysinghe; Paul Shannon; Matthew Gitlin; Sean Robbins Journal: Bone Date: 2012-06-06 Impact factor: 4.398
Authors: H A Bischoff-Ferrari; B Dawson-Hughes; H B Staehelin; J E Orav; A E Stuck; R Theiler; J B Wong; A Egli; D P Kiel; J Henschkowski Journal: BMJ Date: 2009-10-01
Authors: A Catalano; N Morabito; A Di Stefano; E Morini; G Basile; B Faraci; S Loddo; R Ientile; A Lasco Journal: J Endocrinol Invest Date: 2015-05-08 Impact factor: 4.256